

Drug Monograph

Drug/Drug **Lorzone[®] (Chlorzoxazone) Tablet / Centrally Acting**
Class: **Skeletal Muscle Relaxant**
Prepared for: MO HealthNet
Prepared by: ACS, A Xerox Company

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Each Lorzone[®] 375 mg tablet contains 375 mg of chlorzoxazone USP.
Each Lorzone[®] 750 mg tablet contains 750 mg of chlorzoxazone USP.

Manufacturer: Vertical Pharmaceuticals, Inc. Sayreville, NJ 08872

Indications: Lorzone[®] is indicated as adjunct therapy to rest, physical therapy and other measures to relieve the discomforts of acute, painful musculoskeletal disorders.

Costs: \$2.18000 per tablet of Lorzone[®] 375mg and \$2.34000 per tablet of Lorzone[®] 750 mg Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

Status Recommendation: Prior Authorization (PA) Required Open Access
 Clinical Edit PDL

Type of PA Criteria: Increased Risk of ADE Preferred Agent
 Appropriate Indications Under Solicitation

Prepared By: Joshua S. Moore, Pharm. D.
Date: January 24, 2012